Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LncRNA WEE1-AS coordinates oxidative fatty acid metabolism through the activation of mitochondrial Cdk1/Cyclin B1

ABSTRACT: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly prevalent with life-threatening complications, underscoring the need for new therapeutic targets. In this study, we identified a novel long non-coding RNA (lncRNA), WEE1-AS, which is transcribed from the antisense strand of the Wee1 gene locus. Hepatic WEE1-AS was expressed in a spatiotemporal manner in response to a high-fat diet challenge. Functionally, WEE1-AS enhanced mitochondrial fatty acid oxidation by activating the Cdk1/Cyclin B1 complex through two mechanisms. First, it suppressed the transcription of the Wee1 gene by preventing access to the transcriptional machinery. Second, WEE1-AS bound and stabilized the Cyclin B1 protein by suppressing ubiquitin/proteasome-mediated degradation. Notably, treatment with the Wee1 inhibitor Adavosertib ameliorated MASLD symptoms by improving mitochondrial function in the liver. Furthermore, we identified a human homolog, lnc106435.1, which improved mitochondrial function, suggesting that targeting lnc106435.1 could be a valuable therapeutic strategy for managing MASLD.

ORGANISM(S): Mus musculus

PROVIDER: GSE289618 | GEO | 2026/01/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription termination counteracts DNA damage after WEE1 inhibition

Project description:Transcription termination is a key regulatory step in transcription and a potential target for cancer therapy, but how it can be exploited for treatment is incompletely understood. Here we show that transcription termination plays a crucial role in mitigating DNA damage and cell death upon WEE1 inhibition by adavosertib. Depleting five different transcription termination factors (WDR82, PNUTS, XRN2, DDX5 or CPSF73) increased adavosertib-induced DNA damage in S-phase. Conversely, inhibiting active transcription with DRB or triptolide, or co-depleting CDC73, a component of the PAF1 transcription elongation complex, reduced such damage. Additionally, read-through transcription following WDR82 depletion was partially inhibited by co-depletion of CDC73, supporting that read-through transcription contributes to DNA damage in response to WEE1 inhibition. Moreover, combining adavosertib with the CPSF73 inhibitor JTE-607, an anticancer compound which promotes read-through transcription, increased DNA damage during S-phase. Elevated expression of CPSF73 is associated with aggressive disease in prostate cancer patients, and combining JTE-607 with adavosertib synergistically reduced prostate cancer cell survival. Our findings suggest that transcription termination helps prevent toxic conflicts between transcription and replication following increased replication initiation caused by WEE1 inhibition.

2025-12-02 | GSE312256 | GEO

Targeting of WEE1 suppresses tumorigenecity and cancer stem cell-like phenotype in hepatocellular carcinoma

Project description:The current standard-of-care for advanced liver cancer is limited. Therefore, there is an urgent need for development of novel molecular targeted therapy. Increase of WEE1 kinase activity through an epigenetic regulation plays an important role in the development of hepatocellular carcinoma (HCC). Here we demonstrated that WEE1 siRNA silencing caused inhibition of HCC cell growth through blockade of cell cycle progression and induction of apoptosis. The anti-proliferative effects were driven by a subset of molecular alterations including the upregulation of cdk inhibitor p21 and the downregulation of AKT1, CDK2, cyclin B1 (CCNB1), PARP1 and GPAM which are functionally involved in control of cell cycle, apoptosis and lipid metabolism. Systemic delivery of a modified WEE1 siRNA encapsulated in lipid nanoparticles significantly inhibited human HCC growth in murine xenograft models, and increased mice survival. Wee1 silencing in tumor cells also resulted in a strong inhibition of lipogenesis (SREBP1C, FAS) and caused a marked decrease in fat accumulation. Of importance, knockdown of WEE1 dramatically reduced the portion of liver cancer stem cells (CSCs) population through co-downregulation of cancer stemness genes and weakened the capacity of sphere formation and the ability of cancer cell migration. Our findings suggest that the epigenetic modifier WEE1 functionally involve to HCC lipid metabolism and CSC-like phenotype maintenance and that molecular targeting of WEE1 may be an effective systemic therapy for prevention of tumor recurrence via elimination of CSCs in liver tumor microenvironment.

2017-05-31 | GSE68778 | GEO

Liver-Targeted siRNA Therapy Reveals a Causal Role of Metabolic Dysfunction-Associated Steatotic Liver Disease in Brain Dysfunction

Project description:Metabolic-dysfunction-associated steatotic liver disease (MASLD) has traditionally been studied as a liver-centric condition. However, growing clinical and experimental evidence reveals a strong link between MASLD and cognitive impairment and sensorimotor alterations. The mechanisms underlying this liver-brain axis remain poorly defined, and whether hepatic dysfunction alone is sufficient to drive central nervous system deficits is unclear. Using diet-induced non-obese mouse models of MASLD, we performed comprehensive neurocognitive and behavioral assessments. MASLD was associated with marked alterations in social memory, sensorimotor processing, and hippocampal function, including decreased parvalbumin-positive interneurons, reduced dendritic spine density, and diminished indicators of neurogenesis in the hippocampal dentate gyrus. Then, we selectively modulated liver metabolism through a hepatocyte-targeted siRNA therapy against Cyclin M4 (CNNM4), a magnesium transporter dysregulated in MASLD, employing GalNAc-siRNA technology for targeted delivery. Notably, liver-specific intervention with siRNA-CNNM4 reversed features of impaired social memory and sensorimotor processing through recovery of hippocampal synaptogenesis and mitochondrial function pathways, alongside activation of neurogenesis-associated transcriptional programs. Our findings demonstrate that liver pathology is sufficient to drive neurobehavioral and hippocampal dysfunction in MASLD. Importantly, hepatic-specific intervention restores brain function, strongly supporting the existence of a causal and therapeutically targetable liver-brain axis. These results open new avenues for treating MASLD-associated neurological complications through liver-directed therapies.

2025-09-22 | PXD063321 | Pride

Untargeted proteomic analysis of simultaneously collected human liver tissue and plasma of patients with a histological diagnosis of metabolic dysfunction-associated steatotic liver disease.

Project description:The liver tissue and plasma were collected from patients when undergoing liver biopsy for a diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD), along with controls who had no histological abnormalities. The study group included seven patients with no liver histological abnormalities and 64 patients with MASLD across its spectrum, including those with metabolic dysfunction-associated steatotic hepatitis (MASH) and those with cirrhosis. The data were compared between liver tissue and plasma, across various stages of MASLD, and for the detection of biomarkers for different stages of MASLD.

2024-06-07 | MSV000094959 | MassIVE

Hepatocyte-derived Pumilio1-enriched exosomes inhibit HSC activation by suppressing tropomyosin-4 translation

Project description:Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease globally. Abnormal crosstalk between hepatocytes and hepatic stellate cells (HSCs) leads to liver fibrosis and aggravates MASLD. We explored the role of the RNA-binding protein Pumilio in this process.

2025-04-27 | GSE295362 | GEO

Splicing factor CWC22 prevents tetraploidy formation and mitotic slippage through maintenance of the BubR1 expression and CDK1 activity

Project description:Splicing factors play a fundamental role in the process of gene expression. Several splicing factors are highly expressed in cancers and promote the proliferation. Although targeting of splicing factors prolong the duration of G2 phase and mitosis, the involvement of splicing factors in regulation of cell ploidy remains unclear. In this study, we found that knockdown of CWC22, a splicing factor, increased not only the population of G2 phase and mitosis but also tetraploid cells. Notably, CWC22 knockdown induces mitotic slippage, which exhibits rapid mitotic exit without SAC satisfaction after prolonged prometaphase duration. CWC22 knockdown led to cyclin B1 degradation and accumulation of inactive CDK1 having the inhibitory phosphorylation at Tyr15 in mitosis. The cyclin B1 overexpression and Wee1 blockage mitigated the shortage of mitotic duration by CWC22 knockdown. RNA-seq analysis indicated that CWC22 knockdown down-regulated SAC-regulatory genes, including BubR1. The shortage of mitotic duration caused by CWC22 knockdown was also mitigated by both overexpression of BubR1 and Wee1 blockage. Furthermore, CWC22 was highly expressed in pancreatic or cervical cancers, and the higher expression negatively correlated with patients’ prognosis. CWC22 knockdown induced cancer cell death after miotic slippage and prolonged G2 phase due to DNA damage accumulation. These results suggest that CWC22 not only supports proper progression of G2/M phase but also prevents mitotic slippage and tetraploid cell formation via regulation of checkpoint signaling by contributing to the proper expression of BubR1 and the CDK1 activity. These findings reveal a novel splicing factor function in genome stability.

2025-11-25 | GSE310789 | GEO

The non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Phosphoproteomics

Project description:PARP1 inhibitors (PARP1is ) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, olaparib and niraparib), talazoparib displayed the highest potency across SCLC, also in SLFN11-negative cells. Chemical proteomics identified PARP16 as a unique talazoparib target in addition to PARP1. Silencing PARP16 significantly reduced cell survival, particularly in combination with PARP1 inhibition. Drug combination screening revealed talazoparib synergy with the WEE1/PLK1 inhibitor, adavosertib. Global phosphoproteomics identified disparate effects on cell cycle and DNA damage response signaling, illustrating underlying mechanisms. Synergy with adavosertib was more pronounced for talazoparib than olaparib and silencing PARP16 further reduced cell survival in combination with olaparib and adavosertib. Together, these data suggest that PARP16 contributes to talazoparib’s overall mechanism of action and constitutes a new actionable target in SCLC.

2021-07-21 | PXD020484 | Pride

The non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Chemical Proteomics

Project description:PARP1 inhibitors (PARP1is) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, olaparib and niraparib), talazoparib displayed the highest potency across SCLC, also in SLFN11-negative cells. Chemical proteomics identified PARP16 as a unique talazoparib target in addition to PARP1. Silencing PARP16 significantly reduced cell survival, particularly in combination with PARP1 inhibition. Drug combination screening revealed talazoparib synergy with the WEE1/PLK1 inhibitor, adavosertib. Global phosphoproteomics identified disparate effects on cell cycle and DNA damage response signaling, illustrating underlying mechanisms. Synergy with adavosertib was more pronounced for talazoparib than olaparib and silencing PARP16 further reduced cell survival in combination with olaparib and adavosertib. Together, these data suggest that PARP16 contributes to talazoparib’s overall mechanism of action and constitutes a new actionable target in SCLC.

2021-07-21 | PXD020455 | Pride

The non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Expression Proteomics

2021-07-21 | PXD020485 | Pride

Effect of hepatocytic RKIP depletion on HFD-induced MASLD

Project description:High-fat diet (HFD) is a risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD), yet the molecular pathways that connect dietary fats to liver dysfunction remain unclear. Hepatocyte-specific RKIP depletion in male mice exacerbates ER stress, resulting in lipid droplets accumulation and MASLD progression.

2025-09-03 | GSE300123 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data